Alzheimer's drug Simufilam fails to meet trial expectations, Cassava Sciences stock takes major hit

Expected with high hopes by all those affected by Alzheimer's and investors alike, the Phase 3 trial of Cassava Sciences' proprietary small molecule Simufilam failed to deliver the anticipated results.…

Continue Reading Alzheimer's drug Simufilam fails to meet trial expectations, Cassava Sciences stock takes major hit